Wolff Wiese Magana LLC Buys 766 Shares of Neurocrine Biosciences, Inc. $NBIX

Wolff Wiese Magana LLC increased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 982.1% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 844 shares of the company’s stock after acquiring an additional 766 shares during the quarter. Wolff Wiese Magana LLC’s holdings in Neurocrine Biosciences were worth $106,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Dodge & Cox grew its holdings in Neurocrine Biosciences by 83.5% during the first quarter. Dodge & Cox now owns 5,534,624 shares of the company’s stock worth $612,129,000 after buying an additional 2,518,199 shares in the last quarter. Wellington Management Group LLP grew its holdings in Neurocrine Biosciences by 44.0% during the first quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company’s stock worth $232,037,000 after buying an additional 640,556 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Neurocrine Biosciences by 3.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,539,601 shares of the company’s stock worth $170,281,000 after buying an additional 49,088 shares in the last quarter. Braidwell LP grew its holdings in Neurocrine Biosciences by 32.2% during the first quarter. Braidwell LP now owns 1,191,925 shares of the company’s stock worth $131,827,000 after buying an additional 290,135 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Neurocrine Biosciences by 8.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,159,367 shares of the company’s stock worth $128,226,000 after buying an additional 89,271 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

NBIX has been the subject of several recent research reports. Guggenheim upped their price target on Neurocrine Biosciences from $165.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Wedbush restated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, September 22nd. Stifel Nicolaus upped their price objective on Neurocrine Biosciences from $166.00 to $174.00 and gave the company a “buy” rating in a research note on Thursday, July 31st. Wall Street Zen upgraded Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. Finally, Piper Sandler upped their price objective on Neurocrine Biosciences from $154.00 to $175.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Seventeen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $161.89.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX opened at $142.00 on Monday. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $154.61. The business’s fifty day moving average price is $136.39 and its 200-day moving average price is $123.41. The stock has a market capitalization of $14.08 billion, a PE ratio of 42.01, a P/E/G ratio of 1.02 and a beta of 0.28.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.08. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The firm had revenue of $687.50 million for the quarter, compared to analysts’ expectations of $653.09 million. During the same quarter in the prior year, the firm earned $1.63 EPS. The business’s revenue for the quarter was up 16.5% compared to the same quarter last year. As a group, equities analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity

In other news, Director Kevin Charles Gorman sold 106,322 shares of the company’s stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the transaction, the director owned 514,596 shares of the company’s stock, valued at $65,050,080.36. This represents a 17.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jude Onyia sold 59,819 shares of the company’s stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total value of $7,803,986.74. Following the transaction, the insider directly owned 18,289 shares in the company, valued at $2,385,982.94. This represents a 76.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 186,960 shares of company stock valued at $23,955,553 in the last 90 days. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.